You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
Feb 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    relugolix
May 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
May 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
May 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025

Pages